



Raoultella Infections from Clinical to Laboratory- Update & Literature review

Kobra Salimiyan rizi (Ph.D)^{1*}, Hadi Farsiani (Ph.D)²

¹ School of medicine, Isfahan University of Medical Sciences, Isfahan 81744176, Iran.

² Antimicrobial Resistance Research Center, Department of Medical Bacteriology and Virology, Qaem University Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

ARTICLE INFO

Article type

Review article

Article history

Received: 08 Nov 2022

Revised: 15 Nov 2022

Accepted: 01 Dec 2022

Keywords

Klebsiella oxytoca
Laboratory identification
Raoultella planticola
Raoultella species

ABSTRACT

The genus *Raoultella* is yet understudied in comparison with other Enterobacteriales members. However, there are various distributed case reports on *Raoultella* infections. The genetic similarity among *Raoultella* spp. and *Klebsiella* spp. perhaps cause to misidentification using conventional microbiology methods. The prevalence of this bacterium in clinical service can shift geographically. Our knowledge of its resistome evolution contributing to *Raoultella* antibiotic resistance is restricted to a scanty characterized genetic determinates, too. This review summarizes the current understanding on *Raoultella* genetic and microbiology aspects, its identification methods, virulence factors, clinical manifestations, and so on. This combined data significant the crevices in our understanding of *Raoultella* pathogenesis, resistome, and vaccine recommending for future investigating purposes. The diversity and plasticity of the antibiotic resistance plane of *Raoultella* species have determined the early and accurate identification of *Raoultella* infection is exceptionally necessary to progress the guess of the clinical infections and to control the spread of this bacterium. According to our literature review results, patients with multiple congenital abnormalities are susceptible to *Raoultella* infection. Some risks prone to infection include tumors, human immune system disorders, and invasive surgeries.

Please cite this paper as:

Salimiyan rizi K, Farsiani H. *Raoultella* Infections from Clinical to Laboratory- Update & Literature review. *Rev Clin Med*. 2022;9(4): 159-171.

1. Introduction

Raoultella genus is a gram-negative, rod-shape, encapsulated, biofilm forming, non-motile, facultative anaerobic bacterium that currently comprise within *Enterobacteriales* (1). The Klebsiellae tribe, subfamily “*Klebsiella* clade” includes the genera *Klebsiella*, *Raoultella*, *Kluyvera*, *Pluralibacter*, *Trabulsiella*, and *Yokenella* (2,3).

It being found in plants, water and soil, and are known to colonize humans and animals. *Raoultella* is a histamine-producer that causes fish poisoning (4). *Raoultella* changes histidine to histamine as the etiology of histamine poisoning via cutaneous flushing, or as the “scombroid syndrome” related due to fish poisoning (5).

Two species *R. ornithinolytica* and *R. planticola* are mainly isolated from human specimens. But *R. terrigena* and *R. electrica* are rarely isolated from clinical human specimens. *Raoultella planticola* can exist in animal mucus membranes (<https://lpsn.dsmz.de/genus/Raoultella>). The typical reservoirs of *R. planticola* are the upper respiratory tract and the gastrointestinal tract (6,7).

Raoultella spp. are opportunistic bacteria that generally begin infections. The first report of *Raoultella* human infection [1984, France] was in a patient with sepsis (8).

As the late 2000s there has been an excess in case reports of human *Raoultella* infections. Some authors are suggesting that *Raoultella*

*Corresponding author: Kobra Salimiyan rizi,
School of medicine, Isfahan University of Medical Sciences,
Isfahan 81744176, Iran.
E-mail: salimian.k@gmail.com
Tel: 09382657837

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

species are rare and/or emerging pathogens rather than underdiagnosed (9-11).

Most strains of *Raoultella* on solid media grow

in the form of mucous colonies, which is related to forming polysaccharide capsules (12) (Fig1).




Figure 1. (a) *R. terrigena* circular, smooth, glistening, light yellow, and non-hemolysis colonies on sheep blood agar (13). (b) Mucoid, lactose-fermenting colonies of *R. planticola* on MacConkey agar (Wikimedia, commons.wikimedia.org/wiki/File:Raoultella_planticola_MacConkey_colonies). (c) Gram-negative bacilli of *R. ornithinolytica* (Gram staining, 10 × 100 magnification)

The purpose of this review is to summarize the literature about microbiology aspect, clinical manifestations, diagnostic methods, biotechnology applications, and antibiotic therapy aspects of *Raoultella* species based on published reports until now.

2. Clinical Manifestations & Epidemiology

Raoultella is considered as an opportunistic pathogen for human (13). *Raoultella planticola* is involved in severe infections e.g., bloodstream, upper gastrointestinal (GI), pancreatitis, peritonitis, cholangitis, cellulitis, pneumonia and lung abscesses, meningitis, cerebral abscess, mediastinitis, pericarditis, conjunctivitis, mandibular osteomyelitis, otitis, surgical site infections, urinary tract infections, and sepsis following the consumption of seafood (14-16).

Raoultella ornithinolytica can cause pneumonia, biliary or urinary tract infections and bacteremia and similar episodes are being increasingly reported (17,18).

Literature review data that presented at Table 1 indicate the high rate and extended wide infections for *Raoultella* species. One reason/hypothesis for this issue has been supported by Yokota et al. [Japan, 2012] report that *R. planticola* colonizes the gastrointestinal tract and converts a potential origin of infection (19). Atici S et al. [Turkey, 2017] were isolated *Raoultella terrigena* as causative agent of subungual abscess in an infant (20).

Although *R. planticola* is mainly an aquatic and

soil bacterium, it has been clinically isolated from human sputum, stool, wound, blood, discharges, and urine (21). The epidemiology of *Raoultella*-infections incidence might be underestimated (22). The actual incidence of *R. planticola* infections is complex to approximate because of misidentification and underreported cases (23).

The infection via *R. planticola* is correlated with either immunosuppression conditions, for example neoplasia, cancer, chronic renal disease, and diabetes mellitus, or invasive procedures and trauma (24,25).

For example, UTIs by *Raoultella* species occur in immunocompromised, oncological, instrumented or basic urological patients (26). There were 363 cases of *R. terrigena* contamination between 1988 and 2021. The mortality of this disease is approximately 44%, and in 38.6% of cases, *R. terrigena*, has an MDR anti-microbial affectability profile (13).

The species *Raoultella ornithinolytica* determined in 2011 is an emerging bacterium in urogenital tract infections (27).

Raoultella ornithinolytica, have been suggested as opportunistic pathogen that usually infect elderly patients with immunosuppression or co-morbidities, especially solid tumors (28).

Raoultella planticola is considered to have more virulency than the other species, and it is related to with a higher attribute mortality rate (22).

Table 1. Examples of *Raoultella* spp. associated with human infections

Species	Human infections	Location / Time/ Numbers of cases	Underlying diseases	Ref	
R. planticola	• Cardiac implantable device infection	France (2017) / A case	Immunocompromised	(14)	
	• Pneumonia	Korea (2015) / A case	Smoking history	(29)	
	• Cholangitis & Sepsis	Italy (2014) / A case	COPD & bronchiectasis	(30)	
	• Pancreatitis	Brazil (2007) / A case	-----	(31)	
	• Pancreatic pseudocyst	Brazil (2016) / A case	Alcoholic pancreatitis	(32)	
	• Gastroenteritis	Spain (2013) / A case	Hypercholesterolemia, Pituitary adenoma	(33)	
	• Urinary tract infection	USA (2018) / A case	IgA Nephropathy	(34)	
	• Soft-Tissue Infection	Ireland (2010) / A case	-----	(35)	
	• Necrotizing fasciitis	Korea (2012) / A case	Cardiovascular disease, DM	(36)	
	• Conjunctivitis	Malta (2016) / 4 cases	Cataract surgery, scratching with twig	(37)	
	• Prostatitis	Greece(2014) / A case	Renal allograft recipient	(38)	
	• Osteomyelitis & Epidural abscess	USA (2017) / A case	DM, Hypertension, Hyper- lipidemia	(39)	
	• Pelvic cellulitis	Germany (2018) / A case	Neutropenic patient	(40)	
	• Bacteremia & Sepsis	Florida (2017) / A case	Cirrhosis	(41)	
	R. ornithinolytica	• Catheter-related bacteremia	Spain (2017) / A case	Pancreatic cystic neoplasm	(42)
• Conjunctivitis		France (2016) / 4 cases	-----	(43)	
• Enteric fever-like syndrome		Spain (2009) / A case	Arterial hypertension & DA	(44)	
• Skin/wound infection		France (2016) / 2 cases	-----	(43)	
• Pericarditis		France (2016) / A case	-----	(43)	
• Pneumonia		Turkey (2011) / A case	A 16-month-old female child	(45)	
• Diabetic foot infection		USA (2017) / A case	DM, Hypertension, CKD	(46)	
• Prosthetic joint infection		France (2018) / A case	-----	(47)	
• Pansinusitis		USA (2017) A case	Hypertension, poor hygiene life style	(48)	
• Urinary tract infection		France (2016) / 6 cases	-----	(43)	
R. terrigena	• Post-ERCP acute cholangitis, Sepsis	UK (2007) / A case	AHT, obesity	(49)	
	• Gastrointestinal infection	France (2016) / 15 cases	-----	(43)	
	• Fatal Endocarditis	USA (2007) / A case	Liver transplantation, HCV	(50)	
	• Urinary tract infection	Turkey (2015) / A case	Premature newborn	(51)	
	• Endocarditis & Sepsis	UK (2011) / A case	Pancreatic cancer	(52)	
	• Skin (n=4) & UTI (n=4)	Tunisia (2021) / 8 cases	HSCT recipients	(53)	
	• Subungual Abscess	China (2016) / A case	Washing the thumb wound by river water	(54)	
	• Fulminant sepsis	Pakistan (2019) / A case	Uncontrolled diabetes	(55)	
	R. electrica	Not founded any report of human infection due to <i>R. electrica</i>			(56, 57)

Abbreviations: COPD; Chronic Obstructive Pulmonary Disease, DA; degenerative arthropathy, IgA; Immunoglobulin A, DM; Diabetes Mellitus, HSCT recipients; Hematopoietic Stem Cell Transplant recipients, CKD; Chronic Kidney Disease, ERCP; endoscopic retrograde cholangiopancreato-graphy, AHT; arterial hypertension.

Raoultella terrigena is an opportunistic pathogen with a high level of mortality (44%), which may lead to an infection handle with the endogenous source (fecal and bile) as well as an exogenous source (water, drain, and soil) additionally may be related with healthcare-associated infections. However, it is not clear might the *R. terrigena* be a portion of the typical microbiota of the human digestive system or its asymptomatic carriers of the pathogen (13).

The gastrointestinal infections with *Raoultella* are often occurred in individuals with an altered immune system either by a malignant condition, endoscopic procedure, enteral feeding tubes, or a chronic disease(18).

According to some studies, *Raoultella* is able to survive in a domain of hospital environments through developing resistance to disinfectants (58). In study of Zadoks R and et al, [New York, 2011] on dairy farms has been showed that *R. planticola* was the most frequent species among isolates from soil and feed crops (59).

So, these environmental resources are involved in the epidemiology of *Raoultella* species infections. According to the molecular epidemiology studies by 16s-rRNA analysis, it is confirmed that the prevalence of these organisms in clinical settings can vary geographically (60).

3. Genome structure

It is noteworthy that *Raoultella* was initially part of the genus *Klebsiella*, in 1981(61), but later re-classified based on the 16s-rDNA sequence and the *rpo B*, *gyr A*, and *gyr B* genes, in 2001 (62).

Although, the phylogenetic evidence was weak; the genus *Raoultella* did not seem monophyletic in the phylogeny of the partial *rpoB* sequence. Recently, several studies have been performed on *Raoultella* genome structure. Huang YT and et al, [Taiwan-USA, 2018] were sequenced the complete genome of a human clinical isolate *Raoultella planticola* GODA strain (63).

This isolate the genome size, G+ C content, and CDSs was possessed 5,592,163 bp, 55.4%, and 5,461, respectively. The genome of *Raoultella ornithinolytica* strain Marseille-P1025 comprises the chromosome size, G + C %, and CDS content were 5,644,584 bp, 55.6% and 5,260, respectively. In this strain no putative plasmid sequence was detected (47).

In study of Xu S and et al, [China, 2019] the whole genome of *Raoultella* sp. strain X13 has been sequenced (64). The circular chromosome

comprises 5,404,711 bps, which correspond to 4375 protein-coding genes, 1 microsatellite sequence, 74 minisatellite sequences, 25 rRNA genes, and 85 tRNA genes with an average G + C content of 55.94%. Also, the plasmid of *Raoultella* sp. strain X13, possesses 43,768 bps with an average G + C content of 34.90 %.

In another research Fazal MA and et al, [UK, 2019] sequenced the chromosome of *R. terrigena* strain NCTC 13097. This strain has two contigs of 5,574,669 bp, with a GC content of 57.3%. There were 5,386 CDS genes, 84 tRNA genes, and 25 rRNA genes (65).

The genomic diversity and mechanisms of pathogenesis underlying the molecular evolution of this bacterium have not yet been thoroughly investigated (66).

A whole-genome sequencing by Schicklberger M and et al [USA, 2015] on *R. terrigena* R1Gly was performed.

In their study, they found that the draft genome sequence revealed a 5.7-Mb genome with 57.84 mol% GC content, which is comparable to those of the diazotrophs *R. planticola* (5.8 Mb; 55.4 mol%) and *R. ornithinolytica* S12 (5.5 Mb; 57.47 mol%) as well as the non-diazotrophs *R. ornithinolytica* B6 (5.3 Mb; 55.75 mol%) and *R. ornithinolytica* TNT (5.6 Mb; 55.5 mol%) (67).

4. Pathogenicity, Virulency

Raoultella is not a highly virulent pathogen. This bacterium can colonize in gastrointestinal and oropharyngeal tracts of adults and newborns (68). The virulence factors of *Raoultella* are thought to be similar to the ones of *Klebsiella* species due to their phylogenic similarities, however, no such correlation was found in-vivo (69).

Multiple factors can involve in the pathogenesis of diseases arising from the genus of *Raoultella*. These factors include lipopolysaccharide (LPS) (O-antigen), polysaccharide capsule (CPS) (K-antigen), fimbriae, siderophores, toxin, hydrolytic enzymes and bacteriocins (70, 71).

The hemagglutinins, type 1 & type 3 fimbriae, siderophores, enterobactin and occasionally aerobactin are shared between *R. planticola*, *R. terrigena*, and even *K. pneumoniae* (72).

Mannose-sensitive haemagglutination (MSHA) and type 3 pili (MR/K-HA) were observed in some of *R. terrigena* isolates similar to *K. pneumoniae* (73). The polysaccharide capsule is considered a major virulence factor of *R. planticola* (Fig 2) (74).




Figure 2. The genetic diversity in the cps gene cluster of several *Raoultella planticola* strains. Gene clusters are shown in gray. Strain specific wzx genes are marked in red color. GT: glycosyltransferase. [Huang YT & et al, Taiwan-USA; 2018]63

LPS fatty acids profiles of *K. oxytoca*, *R. terrigena*, *R. planticola*, and "*K. trevisanii*" strains were very identical and differed from that of the *K. pneumoniae* strain by higher levels of dodecanoic acid (approximately 5-6 times) and absence of 2-hydroxytetradecanoic acid (75). This obtained data indicated more close relatedness of *K. oxytoca*, *R. terrigena*, and *R. planticola* and some their remoteness from *K. pneumoniae*. In particular, *R. terrigena* expresses a smooth-LPS (S-LPS), Two major factors of virulence, capsular polysaccharide and LPS-O antigen, are involved in mucosal colonization and the development of infections by *Raoultella* (76).

Also, these species can form biofilm (77). The ability to form biofilms, will help us better understand the relationship of *Raoultella* species human infections (e.g., *R. ornithinolytica*) with invasive procedures e.g., implantation of venous catheters, intra-vascular prostheses or orthopedic devices. *R. planticola* pathogenicity and occurrence should be known by clinicians and a high level of awareness is necessary to precisely identify it provide the correct antibiotic regimen (14).

The ability of *R. ornithinolytica* to adhere to human tissues and to form biofilms in urinary catheters is an important issue (78). These two mechanisms could exhibit a role in the pathogenesis of bone and joint infections caused by *R. ornithinolytica*.

The strain *R. ornithinolytica* WM1 encoding the type I fimbriae, *Escherichia coli* common pilus, type II & VI secretion systems, yersiniabactin, enterobactin, and surface polysaccharide (66). A genomic island (RoGI) was determined in *Raoultella ornithinolytica* strain Marseille-P1025 that isolated from

chronic prosthetic joint infection in an immunocompetent illness. This genetic island was specific for *R. ornithinolytica* strains (47). RoGI was presumably obtained via lateral gene transfer from a member of the *Pectobacterium* genus and harbored for a type-IVa SS. It is detected in other pathogenic bacteria and maybe has a role in the virulence and pathogenicity of *R. ornithinolytica* strains. According to several research studies, it is noteworthy that numerous similarities via *K. pneumoniae* and *R. planticola* bacteremia; the biliary tract was a route of entrance in a large portion of cases, and was usual in elderly patients via malignancies (79).

5. Laboratory diagnostic methods

According to the remarkable increase in the frequency of *Raoultella* spp. isolating from clinical samples, it perhaps be related to introduction of methods, which allow for reliable identification of these bacteria assigning them to particular genus and species (80, 81). A retrospective research on 240 blood samples from the collection of the Ramón y Cajal University Hospital laboratory in Madrid [Spain, 2015], via bacteria of the *Klebsiella* genus seen, appeared that 11 of them really included of *Raoultella* genus (28).

A few reports indeed propose that about 20% of *Raoultella* species are misdiagnosis as *Klebsiella* (usually *K. oxytoca*) (82). Also, *R. ornithinolytica* infections in humans perhaps underestimated because that this microorganism is hard to distinguish utilizing phenotypic detection tests. An extended range of different clinical samples have been used for culture and isolation of *Raoultella* species such as bronchoalveolar and lavage fluid samples,

urine, stool, wound, discharges, sputum, blood, and so on.

5. 1 Biochemical tests

The three species belong to the *Raoultella* genus maybe be distinguished based on their characteristic biochemical profiles (71) (Table 2). However, no distinct morphological, physiological, or biochemical phenotype between *Klebsiella* and *Raoultella* has been proved yet (1). Drancourt M and et al. [France, 2001] characterized that growth at 10°C can be the hallmark of the genus *Raoultella* (62).

Raoultella planticola and *R. terrigena* are regularly misidentified as *K. pneumoniae* or *K. oxytoca*; as a result, knowledge on their clinical importance stays poor (note that the validity of genus *Raoultella* that was suggested for the two previous species, has been challenged).

Table 2. Metabolic characteristics of *Raoultella* & *Klebsiella*

Reaction	<i>Raoultella</i>	<i>Klebsiella</i>
Catalase	+	+
Oxidase	-	-
Ferment glucose	+	+
Ferment lactose	+	
Ferment lactose at 44.5 °C	+(Without gas)	
Ferment L-sorbose	+	
Nitrate reduction	+	+
Pigment production δ	+	
Lysine decarboxylase	+	+
Ornithine decarboxylase	-a	-
Histamine production	+	-
Indole	-/+b	-/+c
2, 3-butanediol	+	-/+d
Malonate	+	
Growth at 10 °C	+	-e

Symbols: (+) positive, (-) negative, (-/+) variable reactions, respectively. € *K. oxytoca* indole Positive. a Except with *R. ornithinolytica* (72, 83). b *R. planticola* indole variable. δ Pigment Production on gluconate-ferric citrate agar. d *K. pneumoniae* subsp. *pneumoniae* & *K. oxytoca* Are VP (+). e *K.*

The three species belong to the *Raoultella* genus maybe be distinguished based on their characteristic biochemical profiles (71) (Table 2). However, no distinct morphological, physiological, or biochemical phenotype between *Klebsiella* and *Raoultella* has been proved yet (1). Drancourt M and et al. [France, 2001] characterized that growth at 10°C can be the hallmark of the genus *Raoultella* (62).

Raoultella planticola and *R. terrigena* are regularly misidentified as *K. pneumoniae* or *K. oxytoca*; as a result, knowledge on their clinical importance stays poor (note that the validity of genus *Raoultella* that was suggested for the two previous species, has been challenged).

5.1.1 API® (analytical profile index) test strip

The API20E system (bioMérieux) may be

a standardized distinguishing system for *Enterobacteriales* and other non-fastidious, gram-negative rods which utilizes 21 miniaturized biochemical tests and a database (84). It is named a modified way for same-day enterobacterial identification.

In the study of Appelbaum P and et al. [Maryland, 1982] two usual methods, API 20E & Micro-ID, have been evaluated for *Enterobacteriales* members (85). API during 5 hours distinguished 78.5% of strains to species, 9.5% to genus just, 10.1% as a portion of a range of identifications (SI), and 1.9% incorrect. Micro-ID at 4 hours resulted 90.0% accurate identification to species and 3.3% to genus only, 4.0% SI, and 2.7% incorrect.

API identification of many *Serratia*, *Citrobacter* and *Providencia* strains was to genus only; most incorrect outcomes happened in *Serratia marcescens*. Park J and et al. [2011] appraised the potential of three phenotypic systems (VITEK 2 GN ID card, MicroScan Neg Combo 32 panel, & API 20E) to determine *R. ornithinolytica* in comparison via the genotypic methods on 114 clinical isolates (86).

Their outcomes appeared that VITEK 2 determined all of them as *R. ornithinolytica* (26 isolates). MicroScan and API identified 25 isolates (92.6%) and 24 isolates (88.9%) as *K. oxytoca*, respectively. These isolates were ornithine decarboxylase (ODC) negative in all three phenotypic systems. MicroSeq 500 identified 24 isolates (88.9%) as *R. ornithinolytica*. As the final result, MicroScan & API requires extra biochemical tests to distinguish among ODC-negative *R. ornithinolytica* with *K. oxytoca*.

5. 2 Molecular Genetics Methods

The evaluating of 16s rRNA (16s ribosomal RNA), *rpoB* gene (RNA polymerase subunit B) or *hdc* gene (histidine decarboxylase), also the attendance of *blaORN*, *blaPLA*, and *blaTER* genes may be a substitute to the biochemical identification of *Raoultella* species in the laboratory (28,62,87).

Also, sequencing three housekeeping genes include *rpoB*, *gyrA* (DNA gyrase subunit A), and *parC* (DNA topoisomerase 4 subunit A) with phylogenetic analysis can be useful for accurately taxonomic identifying and species-level discriminating the *Klebsiella/Raoultella* complex (66). In study of Granier S and et al, [France, 2003] *R. ornithinolytica* strains can be distinguished from *K. oxytoca* bacteria via ERIC-1R PCR method (Enterobacterial Repetitive Intergenic Consensus1R PCR) (88).

Kovtunovych G and et al, [Ukraine, 2003] used a PCR way for *pehX* gene of *K. oxytoca* strains, to differentiate this species from *Raoultella* bacterial genus (89).

Enterobacterial isolates of *Raoultella* spp. present a penicillinase-related β -lactam resistance pattern proposing the presence of a chromosomal *bla* gene. PCR and gene sequencing of highly-specific chromosomal class A β -lactamase genes (*bla*-PLA;1123bp, *bla*-ORN;1128bp) as the reference identification methods have been established by Ponce-Alonso M and et al (28,90).

They displayed, the 16s-rRNA sequencing provides no certain outcomes, as this method is not capable to differentiate among *Klebsiella* and *Raoultella* genera. The *bla* gene amplification technique can be utilized to distinguish these species from together.

Also, the *rpo* β -sequencing analysis can correctly identify *Raoultella* isolates with high specificity (28). But, the 16s-rRNA has not the suitable selectivity because of the high homology among the correspondent sequences of both *Klebsiella* and *Raoultella* genera (86).

5.3 Semi-automated/Automated identification systems

Nowadays, the clinical microbiology laboratories are strongly required for the quick and valid detection of microorganisms due to the importance of timely corrected chemotherapy. But, routine strategies are in some cases questionable and appear doubtful results. Nowadays, the automated and semi-automated identification sets (e.g., VITEK®2 systems, BD Phoenix™, VITEK®MS, Bruker Biotyper, Sensititre ArIS 2X) can provide the capability to upgrade sick care, shorten length of stay and decrease health care costs (91).

A) VITEK®-2 compact system

The Vitek® 2 (bioMérieux, Marcy l'Etoile, France) system is a fully automated system that does bacterial identification and antibiotic susceptibility plan. A fluorogenic technique for organism identification and a turbidimetric methodology for susceptibility testing has been applied (92).

The Vitek2 ID-GN card (gram-negative bacillus identification card) identifies 154 species of *Enterobacteriaceae* and a select group of glucose non-fermenting gram-negative bacteria during 10 hours. Vassallo J and et al., [Malta, 2015] reported four cases of *R. planticola* conjunctivitis from the conjunctival swabs that were obtained in their institution from patients

with purulent discharge from one or bilateral eyes (37). A comparative study by Alegría Puig C and et al., [Spain, 2019] has been done on 97 clinical isolates of *Raoultella* species. They have done identification of *R. ornithinolytica* and *R. planticola* by MALDI-TOF MS systems (Vitek MS and Bruker Biotyper) with Vitek2 and API20E systems (93).

The clinical collection isolates of *Raoultella* species were identified with Vitek MS, in parallel via Vitek2 and API, and finally with Bruker Biotyper. Among the two most widely used MALDI-TOF MS platforms, results obtained with Vitek MS were slightly superior to those acquired with the Bruker Biotyper system, with sensitivities and specificities of 98.9/57.9% and 98.8/37.0%, respectively. Also, API galleries permitted genus identification for about 18 (19.7%) isolates.

The MALDI-TOF based Vitek-MSTM system is faster and more efficient than the Vitek2 system or API20E galleries for reliable identification of *R. ornithinolytica* and *R. planticola*. However, Vitek 2 is almost as reliable as Vitek-MS for identification of genus *Raoultella*, it needs 24 hours until results are available. Finally, API galleries do not assign correct identification at the species level of most clinical isolates of *R. ornithinolytica* and *R. planticola*.

The Vitek 2 system (BioMérieux) had five biochemical discriminating tests that can identify ODC-negative *R. ornithinolytica* isolates, but this technique had to be confirmed by molecular identification by 16s-rRNA gene sequencing due to the lack of specificity (43).

B) BacT/ALERT® culture system

BacT/Alert (bioMérieux, Marcy l'Etoile, France) is a fully automated continuously monitored blood culture system for detecting bacteria and fungi from all of the sterile body fluids. The colourimetric technology and sophisticated algorithms minimize false-negative results for it (94).

The specialized liquid emulsion sensors (LES) at the bottom of each culture bottle visibly change colour when the pH changes due to the increase in CO₂ gas as it is made with microorganisms. Chun S and et al., [2014, Korea] diagnosed 20 cases of *R. planticola* bacteremia (22).

They isolated microbes from blood culture-positive specimens by utilizing the BacT/ALERT culture media system. However, microbe identification and antibiotic susceptibility tests were done applying the automated VITEK 2 system accompanied via conventional bacteriologic techniques. All isolates were

determined via a probability score exceeding 96% with VITEK 2 system.

C) Phoenix automated microbiology system

The BD-Phoenix™ automated identification and susceptibility testing system (BD Diagnostic Systems, Sparks, MD) for the identification (ID) & antimicrobial susceptibility testing (AST). It can analyze up to 100 combination ID and AST panels simultaneously. The time required to get a perfect set of ID & AST results varies around 8 to 12 h and is dependent on the bacteria tested (95).

Both growth-based and enzymatic substrates are applied to support the various kinds of reactivity in the range of taxa. The Phoenix AST technique is a broth based microdilution test. Yan Y and et al. [China, 2011] found 2 *Raoultella* species that were determined as *K.*

oxytoca by BD-Phoenix ID system, have been identified as *Raoultella* species by MALDI-TOF MS (96). The BD-Phoenix system exhibits complex issues, e.g., that of *R. planticola* not being included in its database. To date, MicroScan and BD Phoenix systems are able to identify *R. ornithinolytica*, but not *R. planticola* or *R. terrigena* (97).

5. 4 MALDI-TOF Mass Spectrometry

Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) method has been utilized for identification of bacterial isolates, illustrated in general great execution within the recognizable of gram-negative bacilli (98), and can correctly identify and differentiate *Klebsiella* from *Raoultella* spp. Initial reports displayed some misidentifications, but supplementation of databases should improve efficiency (99). Therefore, MALDI-TOF mass spectrometry is reliable in identifying the genus *Raoultella* (100).

In research of Jong E et al., [the Netherlands, 2013] 99 clinical isolates formerly determined as *Klebsiella oxytoca* that identified

again with MALDI-TOF MS. According to their results, eight isolates were identified as *Raoultella* spp. (8.08%) (101).

In the study of Jong E and et al., a minimum difference of 10% among the top score with next closest scores was needed for individual isolates (referred to as the 10% differential rule in MALDI-TOF). Martiny D and et al. [Belgium, 2012] found one *R. ornithinolytica* isolate and also one *R. planticola* isolate that could not be detected via VITEK or the Saramis (Axima Assurance-Saramis database; bioMérieux) MALDI-TOF-MS system, but were correctly determined via the Bruker MALDI-TOF MS system to the species and genus levels, respectively (102).

6. Antibiotic therapy & Resistome

The notification of the clinicians with respect to the study of disease transmission and susceptibility levels of *Raoultella* is of the most extreme significance. *Raoultella* species presented intrinsic resistance to ampicillin (similarly to some *Klebsiella* spp.) because of chromosomally encoded beta-lactamase enzymes (18).

Species from both *Raoultella* and *Klebsiella* genera are intrinsically resistant to penicillins because of the expression of an Ambler class A β -lactamase: LEN-1 or SHV-1 in *K. pneumoniae*, K1 in *K. oxytoca*, and PLA-1, ORN-1, and TER-1 in *R. planticola*, *R. ornithinolytica*, and *R. terrigena*, respectively (103).

In addition to the intrinsic resistance determinants, the acquisition and circulating of the antibiotic resistance genes (ARGs) among all of the bacteria help to the development of the "resistome" of bacteria (Table 3).

Table 3. The antibiotic-resistance determinants have been published by studies in our literature review

R. planticola	R. ornithinolytica	R. terrigena	ESBL	Ref
blaCTX-M-9 group			+	(105)
	blaIMP-4 + blaKPC-2		blaTEM-1, blaSHV-12, blaOXA-1	(110)
	blaOXA-48 α		-	(111)
	blaNDM-1 + blaCTX-M-3, bla TX-M-14		+	(112)
blaIMP-8 *			-	(113)
blaKPC-3, blaKPC-2 (2 isolates)	blaKPC-3 (1 isolate)		blaTEM-1, blaSHV-7	(114)
	blaOXA-162, blaOXA-1		blaTEM-1, blaSHV-5	(115)
	blaNDM-1 + blaKPC-2 μ		ND	(116)
blaOXA-48			-	(106)
		**		

Symbols: * Plasmidic carbapenemase, α The blaOXA-48-like gene has been found related via Tn1999 in Enterobacteriales. μ Both of these genes were harbored on a different plasmid. **Any molecular genetic epidemiology study of the Antibiotic resistance genes has not been published for *R. terrigena* until October 2021. ND; not determined.

This resistance evolution occurs among *Raoultella* species, too. *Raoultella planticola*, similar with other *Raoultella* species, carries a chromosomal β -lactamase that makes this agent naturally resistant to multiple antimicrobial agents (31). However, until now, antimicrobial resistance (AMR) of *Raoultella* that causing human infections has not been analyzed systematically. In study of Chen X and et al, [China, 2020] all of the four cases of neonatal septicemia that caused by *R. planticola* strains were only sensitive to amikacin, but resistant to other groups of drugs: cephalosporins (e.g., cefazolin, cefotetan, etc.) and penicillins (e.g., ampicillin-sulbactam, piperacillin, etc.), and even developed resistance to carbapenem (104).

Most, not all, of the case reports include of *Raoultella* species that encoding extended spectrum β -lactamases (ESBLs) and carbapenemase genes have been from Europe and the USA regions (105).

The antibiotic susceptibility of *R. planticola* has not been completely explored, however. Most researches have displayed that *R. planticola* strains are frequently susceptible to third or fourth generation cephalosporin, β -lactamase inhibitor combinations (e.g., amoxicillin-clavulanic & piperacillin-tazobactam), aminoglycosides (AGs), netilmicin, ciprofloxacin, levofloxacin, tigecycline and carbapenems. Although, *R. planticola* can acquire plasmid-mediated antibiotic resistance (9). Also, several studies have reported isolates of *R. ornithinolytica* and *R. planticola*, which are resistant to carbapenem and carry different carbapenemases, including *blaKPC*, *blaOXA-48*, and *blaOXA-162* genes (106). In the report of Castanheira M et al, has been displayed that all patients with infections due to KPC-producing *Raoultella* infections have been received antimicrobial therapy with carbapenems that could have facilitated selection of *Raoultella*

strains resistant to these agents (107).

Eminently, broad utilization of third-generation cephalosporins and other β -lactam antibiotics in the past decades has led the appearance of third-generation cephalosporin-resistant bacteria (e.g., *Raoultella*) that generate ESBLs and AmpC β -lactamases that are, respectively, harbored via plasmids and chromosomes (108, 109).

However, MDR strains of *Raoultella* have been explained, producing a diversity of β -lactamases (Ambler class A, B and D), including SHV-, TEM- and CTX-M-type ESBLs and these bacteria have been presented as potential sources for carbapenemase and colistin-resistance genetic determines (10). In study of Whang S and et al, [China, 2019] were report that the presence of conjugative *blaNDM-1* and *blaCTX-M* plasmids in *R. ornithinolytica* isolates from healthy humans, which determine the possibility of inter-species transfer of drug resistance genes (117).

According to the diversity and plasticity of the antibiotic resistance plane of *Raoultella* species, so early and accurate identification of *Raoultella* infection is exceptionally necessary to progress the guess of the clinical infections and to control the spread of this bacterium.

7. Biotechnology applications

7.1 *R. terrigena* against root-knot nematodes

Today, *Raoultella terrigena* is considered as biocontrol agents against root-knot nematodes (anti-parasitic activity). Li GJ and et al., [China, 2014] discovered the nematicidal effect of *Raoultella terrigena* (strain RN16) against *Meloidogyne incognita* as a parasite of crops (root-knot nematode - RKN) (Fig3). Several researches have confirmed that treating the cultivated herbs with just *R. terrigena* suspension, and in formulation via fresh wasabi extract, efficiently kills *Meloidogyne incognita* on tomatoes (118).



Figure 3. (a) Root-knot nematode disease caused by *Meloidogyne incognita* nematode (119). (b) The root galls & *M. incognita* egg masses on cucumber root (120). (c) Close-up view of different gall sizes of tomato roots (121). (d) The patchy area due to root-knot nematode (*Meloidogyne* spp.) infestation on tomato (121)

Raoultella terrigena may well be disconnected from the digestive system of pufferfish, milk and perhaps be utilized in biotechnology as 2,3-Butanediol producer (13).

7.2 R. ornithinolytica against Acanthamoeba castellanii

The ability of *R. ornithinolytica* to multiply and create cytopathic effect in *Acanthamoeba castellanii* appears to be correlated with its virulence and therefore *R. ornithinolytica* has potential as biological control agent for this trophozoite (122).

Acanthamoeba castellanii is an opportunistic free-living amoeba can cause infections such as meningoencephalitis, ocular keratitis, cutaneous acanthamebiasis in human (123). The presence of a conjugative pili and the capacity of strain *R. ornithinolytica* Marseille-P1025 to invade, survive and multiply in an amoeba (*Acanthamoeba castellanii*) affirms the nearness of type IVa secretion system (47).

8. Identified Areas of Further Research

1. Awareness of Raoultella correct identification and its linked antibiotic resistance complications among clinical diagnostic laboratories.

2. Do we can we develop an efficient vaccine against Raoultella species (especially for high risk patients and newborns)?

3. Do we can we develop the new therapy methods for combating with MDR Raoultella infections other than antibiotic therapy?

4. Determination of molecular epidemiology of antibiotic resistance genes among *R. terrigena* isolates.

9. Conclusion

The genetic similarity between *Raoultella* spp. and *Klebsiella* spp. perhaps cause the misidentifications using biochemical tests such as the Vitek 2 system, the introduction of *rpoB* & 16s-rRNA genes analysis and the novel technology-based in MALDI-TOF MS permissible us a correct identification to species level of *Raoultella* spp.

Also, the diversity and plasticity of the antibiotic resistance plane of *Raoultella* species, has determined the early and accurate identification of *Raoultella* infection is exceptionally necessary to progress the guess of the clinical infections and to control the spread of this bacterium. According to our literature review results, patients that have multiple congenital disorders are more susceptible to *Raoultella* infections.

Some risks prone to infection include tumors, human immune system disorders, and invasive surgeries.

Abbreviations: NCTC; National Collection of Type Cultures, CDS; protein-coding genes, RKN; root-knot nematode, MDR; multi-drug resistance, AGs; aminoglycosides, ESBLs: Extended spectrum β -lactamases, ID; identification, AST; antimicrobial susceptibility testing, MSHA; Mannose-sensitive haemagglutination, LPS; lipopolysaccharide.

Declaration of competing interest

The authors declare that they have no known competing financial interests.

References

1. Ma Y, Wu X, Li S, et al, An Q. Proposal for reunification of the genus Raoultella with the genus Klebsiella and reclassification of Raoultella electrica as Klebsiella electrica comb. nov. *Research in Microbiology*. 2021:103851.
2. Forsythe SJ, Abbott SL, Pitout J. Klebsiella, Enterobacter, Citrobacter, Cronobacter, Serratia, Plesiomonas, and other Enterobacteriaceae. *Manual of clinical microbiology*. 2015:714-737.
3. Alnajar S, Gupta RS. Phylogenomics and comparative genomic studies delineate six main clades within the family Enterobacteriaceae and support the reclassification of several polyphyletic members of the family. *Infection, Genetics and Evolution*. 2017;54:108-127.
4. Kanki M, Yoda T, Tsukamoto T, et al. Klebsiella pneumoniae produces no histamine: Raoultella planticola and Raoultella ornithinolytica strains are histamine producers. *Applied and Environmental Microbiology*. 2002;68:3462-3466.
5. Yamakawa K, Yamagishi Y, Miyata K, et al. Bacteremia caused by Raoultella ornithinolytica in two children. *The Pediatric infectious disease journal*. 2016;35:452-453.
6. Venkataramanan SVA, George L, Sahu KK, et al. A 5-Year Retrospective Analysis of Raoultella planticola Bacteriuria. *Infection and Drug Resistance*. 2021;14:1989.
7. Sekowska A. Raoultella spp.—clinical significance, infections and susceptibility to antibiotics. *Folia microbiologica*. 2017;62:221-227.
8. Freney J, Fleurette J, Gruer L, et al. Klebsiella trevisanii colonisation and septicaemia. *The Lancet*. 1984;323:909.
9. Atıcı S, Ünkar ZA, Demir SÖ, et al. A rare and emerging pathogen: Raoultella planticola identification based on 16S rRNA in an infant. *Journal of infection and public health*. 2018;11:130-132.
10. Gajdacs M. Epidemiology of Raoultella species in the context of human infections: A 10-year retrospective study in a tertiary-care hospital in Hungary. *Trends in Medicine*. 2020;20:Azonosító: 217-Terjedelem: 4 p.
11. Westerveld D, Hussain J, Aljaafareh A, et al. A rare case of Raoultella planticola pneumonia: an emerging pathogen. *Respiratory medicine case reports*. 2017;21:69-70.
12. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical microbiology reviews*. 1998;11:589-603.
13. Lekhniuk N, Fesenko U, Pidhirnyi Y, et al. Raoultella terrigena: Current state of knowledge, after two recently identified clinical cases in Eastern Europe. *Clinical Case Reports*. 2021;9.
14. Adjodah C, D'Ivernois C, Leyssene D, et al. A cardiac implantable device infection by Raoultella planticola in an immunocompromized patient. *JMM case reports*. 2017;4.
15. Lam PW, Salit IE. Raoultella planticola bacteremia following consumption of seafood. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2014;25:e83-e84.
16. Lam PW, Tadros M, Fong IW. Mandibular osteomyelitis due to Raoultella species. *JMM case reports*. 2018;5.
17. Sekowska A, Dylewska K, Gospodarek E, et al. Catheter-related

- blood stream infection caused by *Raoultella ornithinolytica*. *Folia microbiologica*. 2015;60:493-495.
18. Hajjar R, Ambaraghassi G, Sebahaj H, et al. *Raoultella ornithinolytica*: emergence and resistance. *Infection and drug resistance*. 2020;13:1091.
 19. Yokota K, Gomi H, Miura Y, et al. Cholangitis with septic shock caused by *Raoultella planticola*. *Journal of medical microbiology*. 2012;61:446-449.
 20. Wang Y, Jiang X, Xu Z, et al. Identification of *Raoultella terrigena* as a rare causative agent of subungual abscess based on 16S rRNA and housekeeping gene sequencing. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2016;2016.
 21. Hajiyeva K, Oral M. *Raoultella planticola* Bacteremia-Induced Fatal Septic Shock and Sepsis-Induced Coagulopathy in a Patient with Pancreatic Cancer: A Case Report and Literature Review. *International Journal of Clinical Medicine*. 2021;12:36.
 22. Chun S, Yun J, Huh H, et al. Low virulence? Clinical characteristics of *Raoultella planticola* bacteremia. *Infection*. 2014;42:899-904.
 23. de Campos FPF, Guimarães TB, Lovisolo SM. Fatal pancreatic pseudocyst co-infected by *Raoultella planticola*: an emerging pathogen. *Autops Case Rep*. 2016;6:27-31.
 24. Hadano Y, Tsukahara M, Ito K, Suzuki J, et al. *Raoultella ornithinolytica* bacteremia in cancer patients: report of three cases. *Internal Medicine*. 2012;51:3193-3195.
 25. Ershadi A, Weiss E, Verduzco E, et al. Emerging pathogen: a case and review of *Raoultella planticola*. *Infection*. 2014;42:1043-1046.
 26. Pérez PR. Tract infections by the genus *Raoultella*. Literature review and contribution of 1 case of *Raoultella ornithinolytica*. *Archivos españoles de urología*. 2021;74:276-286.
 27. Fanny PSBMB. Emerging role of *Raoultella ornithinolytica* in human. *Diagn Microbiol Infect Dis*. 2013;75:431-433.
 28. Ponce-Alonso M, Rodríguez-Rojas L, Del Campo R, et al. Comparison of different methods for identification of species of the genus *Raoultella*: report of 11 cases of *Raoultella* causing bacteraemia and literature review. *Clinical Microbiology and Infection*. 2016;22:252-257.
 29. Cho YJ, Jung EJ, Seong JS, et al. A case of pneumonia caused by *Raoultella planticola*. *Tuberculosis and respiratory diseases*. 2016;79:42-45.
 30. Salmaggi C, Ancona F, Olivetti J, et al. *Raoultella planticola*-associated cholangitis and sepsis: a case report and literature review. *QJM: An International Journal of Medicine*. 2014;107:911-913.
 31. Alves M, Riley L, Moreira B. A case of severe pancreatitis complicated by *Raoultella planticola* infection. *Journal of Medical Microbiology*. 2007;56:696-698.
 32. de Campos FPF, Guimarães TB, Lovisolo SM. Fatal pancreatic pseudocyst co-infected by *Raoultella planticola*: an emerging pathogen. *Autops Case Rep*. 2016;6:27.
 33. Puerta-Fernandez S MLF, Sanchez-Simonet MV, Bernal-Lopez MR, Gomez-Huelgas R. *Raoultella planticola* bacteraemia secondary to gastroenteritis. *Clinical Microbiology and Infection*. 2013;19:E236-237.
 34. Mehmood H, Pervin N, Israr UI et al. A rare case of *Raoultella planticola* urinary tract infection in a patient with immunoglobulin A nephropathy. *Journal of investigative medicine high impact case reports*. 2018;6:2324709618780422.
 35. O'Connell K, Kelly J, NiRiain U. A rare case of soft-tissue infection caused by *Raoultella planticola*. *Case Reports in Medicine*. 2010;2010.
 36. Kim S-H, Roh KH, Yoon YK, et al. Necrotizing fasciitis involving the chest and abdominal wall caused by *Raoultella planticola*. *BMC infectious diseases*. 2012;12:1-3.
 37. Vassallo J, Vella M, Cassar R, Caruana P. Four cases of *Raoultella planticola* conjunctivitis. *Eye*. 2016;30:632-634.
 38. Koukoulaki M, Bakalis A, Kalatzis V, B et al. Acute prostatitis caused by *Raoultella planticola* in a renal transplant recipient: a novel case. *Transplant Infectious Disease*. 2014;16:461-464.
 39. Subedi R, Dean R, Li W, et al. A novel case of *Raoultella planticola* osteomyelitis and epidural abscess. *Case Reports*. 2017;2017:bcr-2017-220329.
 40. Al-Sawaf O, Garcia-Borrega J, Vehreschild J, et al. Fätkenheuer Pelvic cellulitis caused by *Raoultella planticola* in a neutropenic patient. *Journal of Infection and Chemotherapy*. 2019;25:298-301.
 41. Povlow MR, Carrizosa J, Jones A. *Raoultella planticola*: bacteremia and sepsis in a patient with cirrhosis. *Cureus*. 2017;9.
 42. González-Castro A, Rodríguez-Borregán J, Campos S, et al. Catheter-related bacteraemia caused by *Raoultella ornithinolytica*. *Revista Española de Anestesiología y Reanimación (English Edition)*. 2018;65:116-118.
 43. Seng P, Boushab BM, Romain F, et al. Emerging role of *Raoultella ornithinolytica* in human infections: a series of cases and review of the literature. *International Journal of Infectious Diseases*. 2016;45:65-71.
 44. Morais VP, Daporta MT, Bao AF, et al. Enteric fever-like syndrome caused by *Raoultella ornithinolytica* (*Klebsiella ornithinolytica*). *Journal of clinical microbiology*. 2009;47:868-869.
 45. Sener D, Cokhras H, Camcioglu Y, et al. *Raoultella* infection causing fever of unknown origin. *The Pediatric infectious disease journal*. 2011;30:1122-1123.
 46. Solak Y, Gul EE, Atalay H, et al. A rare human infection of *Raoultella ornithinolytica* in a diabetic foot lesion. *Ann Saudi Med*. 2011;31:93-94.
 47. Beye M, Hasni I, Seng P, et al. Genomic analysis of a *Raoultella ornithinolytica* strain causing prosthetic joint infection in an immunocompetent patient. *Scientific reports*. 2018;8:1-10.
 48. Gore MR. Severe Pansinusitis Due to *Raoultella Ornithinolytica*. *American journal of infectious diseases*. 2017;13:28-31.
 49. Teo I, Wild J, Ray S, et al. A rare case of cholecystitis caused by *Raoultella planticola*. *Case reports in medicine*. 2012;2012.
 50. Goegele H, Ruttmann E, Aranda-Michel J, et al. Fatal endocarditis due to extended spectrum betalactamase producing *Klebsiella terrigena* in a liver transplant recipient. *Wiener Klinische Wochenschrift*. 2007;119:385-386.
 51. Demiray T, Köroğlu M, Özbek A, Hafizoğlu T, Altındiş M. The first case of *Raoultella terrigena* infection in an infant. *Turk J Pediatr*. 2015;57:624-628.
 52. Shaikh MM, Morgan M. Sepsis caused by *Raoultella terrigena*. *JRSM short reports*. 2011;2:1-3.
 53. Mellouli A, Chebbi Y, Raddaoui A, et al. *Raoultella terrigena* infections in hematopoietic stem cell transplant recipients: High rate of mortality in multidrug-resistant strains-A retrospective observational study. *Indian Journal of Transplantation*. 2021;15:118.
 54. Wang Y, Jiang X, Xu Z, et al. Identification of *Raoultella terrigena* as a Rare Causative Agent of Subungual Abscess Based on 16S rRNA and Housekeeping Gene Sequencing. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2016;2016:3879635.
 55. Mal PB, Sarfaraz S, Herekar F, et al. Clinical manifestation and outcomes of multi-drug resistant (MDR) *Raoultella terrigena* infection-A case series at Indus Health Network, Karachi, Pakistan. *IDCases*. 2019;18:e00628.
 56. Kimura Z-i, Chung KM, Itoh H, et al. *Raoultella electrica* sp. nov., isolated from anodic biofilms of a glucose-fed microbial fuel cell. *International journal of systematic and evolutionary microbiology*. 2014;64(Pt 4):1384-1388.
 57. Jain A, Yadav R. First report of isolation and antibiotic susceptibility pattern of *Raoultella electrica* from table eggs in Jaipur, India. *New microbes and new infections*. 2018;21:95-99.
 58. Momeni SS, Tomlin N, Ruby JD. Isolation of *Raoultella planticola* from refillable antimicrobial liquid soap dispensers in a dental setting. *The Journal of the American Dental Association*. 2015;146:241-245.
 59. Zadoks R, Griffiths H, Munoz M, et al. Sources of *Klebsiella* and *Raoultella* species on dairy farms: be careful where you walk. *Journal of dairy science*. 2011;94:1045-1051.
 60. Murray PR, Rosenthal KS, Pfaller MA. *Medical microbiology* E-book: Elsevier Health Sciences; 2020.
 61. Bagley ST, Seidler RJ, Brenner DJ. *Klebsiella planticola* sp. nov.: a new species of Enterobacteriaceae found primarily in nonclinical environments. *Current Microbiology*. 1981;6:105-109.

62. Drancourt M, Bollet C, Carta A, et al. Phylogenetic analyses of *Klebsiella* species delineate *Klebsiella* and *Raoultella* gen. nov., with description of *Raoultella ornithinolytica* comb. nov., *Raoultella terrigena* comb. nov. and *Raoultella planticola* comb. nov. *International journal of systematic and evolutionary microbiology*. 2001;51:925-932.
63. Huang YT, Chuang W-Y, Ho B-C, et al. Comparative genomics reveals diverse capsular polysaccharide synthesis gene clusters in emerging *Raoultella planticola*. *Memórias do Instituto Oswaldo Cruz*. 2018;113.
64. Xu S, Luo X, Xing Y, et al. Complete genome sequence of *Raoultella* sp. strain X13, a promising cell factory for the synthesis of CdS quantum dots. *3 Biotech*. 2019;9:1-5.
65. Fazal M-A, Alexander S, Grayson NE, et al. Complete Whole-Genome Sequences of Two *Raoultella terrigena* Strains, NCTC 13097 and NCTC 13098, Isolated from Human Cases. *Microbiol Resour Announc*. 2019;8:e00239-19.
66. Wang M, Fan Y, Liu P, et al. Genomic insights into evolution of pathogenicity and resistance of multidrug-resistant *Raoultella ornithinolytica* WM1. *Annals of the New York Academy of Sciences*. 2021.
67. Schicklberger M, Shapiro N, Loqué D, et al. Draft genome sequence of *Raoultella terrigena* R1Gly, a diazotrophic endophyte. *Genome Announc* 3: e00607-15. 2015.
68. Podschun R, Aktun H, Okpara J, et al. Isolation of *Klebsiella planticola* from newborns in a neonatal ward. *Journal of Clinical Microbiology*. 1998;36:2331-2332.
69. Demiray T, Koroglu M, Ozbek A, et al. A rare cause of infection, *Raoultella planticola*: emerging threat and new reservoir for carbapenem resistance. *Infection*. 2016;44:713-717.
70. Podschun R, Pietsch S, Höller C, et al. Incidence of *Klebsiella* species in surface waters and their expression of virulence factors. *Appl Environ Microbiol*. 2001;67:3325-3357.
71. Sękowska A. The many faces of *Raoultella* spp. *Advances in Hygiene & Experimental Medicine/Postępy Higieny i Medycyny Doswiadczalnej*. 2019;73.
72. Appel TM, Quijano-Martínez N, De La Cadena E, et al. Microbiological and Clinical Aspects of *Raoultella* spp. *Frontiers in public health*. 2021:1125.
73. Podschun R, Fischer A, Ullmann U. Characterization of *Klebsiella terrigena* strains from humans: haemagglutinins, serum resistance, siderophore synthesis, and serotypes. *Epidemiology & Infection*. 2000;125:71-78.
74. Podschun R, Fischer A, Ullman U. Expression of putative virulence factors by clinical isolates of *Klebsiella planticola*. *Journal of medical microbiology*. 2000;49:115-119.
75. Vasyurenko ZP, Opanasenko LS, Koval GM, et al. Cellular and lipopolysaccharide fatty acid composition of the type strains of *Klebsiella pneumoniae*, *Klebsiella oxytoca*, and *Klebsiella nonpathogenic* species. *Mikrobiol Z*. 2001;63:13-21.
76. Evrard B, Balestrino D, Dosgilbert A, et al. Roles of capsule and lipopolysaccharide O antigen in interactions of human monocyte-derived dendritic cells and *Klebsiella pneumoniae*. *Infect Immun*. 2010;78:210-219.
77. Narisawa N, Haruta S, Arai H, et al. Coexistence of antibiotic-producing and antibiotic-sensitive bacteria in biofilms is mediated by resistant bacteria. *Appl Environ Microbiol*. 2008;74:3887-3894.
78. Seng P, Theron F, Honnorat E, et al. *Raoultella ornithinolytica*: An unusual pathogen for prosthetic joint infection. *IDCases*. 2016;5:46-8.
79. Meatherall BL, Gregson D, Ross T, Pitout JD, Laupland KB. Incidence, risk factors, and outcomes of *Klebsiella pneumoniae* bacteremia. *The American journal of medicine*. 2009;122:866-873.
80. Monnet D, Freney J, Brun Y, et al. Difficulties in identifying *Klebsiella* strains of clinical origin. *Zentralblatt für Bakteriologie*. 1991;274(4):456-64.
81. Westbrook GL, O'Hara CM, Roman SB, Miller JM. Incidence and identification of *Klebsiella planticola* in clinical isolates with emphasis on newborns. *Journal of Clinical Microbiology*. 2000;38:1495-1497.
82. Mori M, Ohta M, Agata N, et al. Identification of species and capsular types of *Klebsiella* clinical isolates, with special reference to *Klebsiella planticola*. *Microbiology and immunology*. 1989;33:887-895.
83. Chun S, Yun J, Huh H, et al. Clinical characteristics of *Raoultella ornithinolytica* bacteremia. *Infection*. 2015;43:59-64.
84. Ferris RA, Palmer BA, Borlee BR, et al. Ability of chromogenic agar, MALDI-TOF, API 20E and 20 strep strips, and BBL crystal enteric and gram-positive identification kits to precisely identify common equine uterine pathogens. *Journal of equine veterinary science*. 2017;57:35-40.
85. Appelbaum PC, Arthur RR, Parker ME, et al. Comparison of Two Methods for Same-Day Identification of Enterobacteriaceae. *American Journal of Clinical Pathology*. 1982;78:351-355.
86. Park JS, Hong KH, Lee HJ, et al. Evaluation of three phenotypic identification systems for clinical isolates of *Raoultella ornithinolytica*. *Journal of medical microbiology*. 2011;60:492-499.
87. Walckenaer E, Poirel L, Leflon-Guibout V, et al. Genetic and biochemical characterization of the chromosomal class A β -lactamases of *Raoultella* (formerly *Klebsiella*) *planticola* and *Raoultella ornithinolytica*. *Antimicrobial agents and chemotherapy*. 2004;48:305-312.
88. Granier SA, Leflon-Guibout V, Goldstein FW, et al. Enterobacterial Repetitive InterGenic Consensus 1R PCR Assay for Detection of *Raoultella* sp. Isolates among Strains Identified as *Klebsiella oxytoca* in the Clinical Laboratory. *Journal of Clinical Microbiology*. 2003;41:1740-1742.
89. Kovtunovych G, Lytvynenko T, Negrutska V, et al. Identification of *Klebsiella oxytoca* using a specific PCR assay targeting the polygalacturonase *pehX* gene. *Research in Microbiology*. 2003;154:587-592.
90. Pas ML, Vanneste K, Bokma J, et al. Case report: multidrug resistant *Raoultella ornithinolytica* in a septicemic calf. *Frontiers in Veterinary Science*. 2021;8:631716.
91. Wrenn C. Introduction of the VITEK 2 Compact and Implementation of EUCAST Guidelines in a Microbiology Department: Royal College of Surgeons in Ireland; 2015.
92. Pincus DH. Microbial identification using the bioMérieux Vitek® 2 system. *Encyclopedia of Rapid Microbiological Methods* Bethesda, MD: Parenteral Drug Association. 2006:1-32.
93. de Alegría Puig CR, Torres MF, et al. Comparison between Vitek MS, Bruker Biotyper, Vitek2, and API20E for differentiation of species of the genus *Raoultella*. *European Journal of Clinical Microbiology & Infectious Diseases*. 2019;38:467-470.
94. Thorpe TC, Wilson M, Turner J, et al. BacT/Alert: an automated colorimetric microbial detection system. *Journal of clinical microbiology*. 1990;28:1608-1612.
95. Donay JL, Mathieu D, Fernandes P, et al. Evaluation of the automated phoenix system for potential routine use in the clinical microbiology laboratory. *Journal of clinical microbiology*. 2004;42:1542-1546.
96. Yan Y, Meng S, Bian D, et al. Comparative evaluation of Bruker Biotyper and BD Phoenix systems for identification of bacterial pathogens associated with urinary tract infections. *Journal of clinical microbiology*. 2011;49:3936-3939.
97. Ombelet S, Natale A, Ronat J-B, et al. Evaluation of MicroScan Bacterial Identification Panels for Low-Resource Settings. *Diagnostics*. 2021.
98. Manji R, Bythrow M, Branda JA, et al. Multi-center evaluation of the VITEK® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli. *European journal of clinical microbiology & infectious diseases*. 2014;33:337-346.
99. Richter S, Sercia L, Branda J, et al. Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the VITEK MS system. *European journal of clinical microbiology & infectious diseases*. 2013;32:1571-1578.
100. Sekowska A, Mikucka A, Gospodarek-Komkowska E. Identification of *Raoultella* spp.: Comparison of three methods. *Indian J Med Microbiol*. 2018;36:197-200.
101. de Jong E, de Jong AS, Smidts-van den Berg N, Rentenaar RJ. Differentiation of *Raoultella ornithinolytica/planticola* and *Klebsiella oxytoca* clinical isolates by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. *Diagn Microbiol Infect Dis*. 2013;75:431-433.

102. Martiny D, Busson L, Wybo I, et al. Comparison of the Microflex LT and Vitek MS systems for routine identification of bacteria by matrix-assisted laser desorption ionization–time of flight mass spectrometry. *Journal of clinical microbiology*. 2012;50:1313-1325.
103. Walckenaer E, Delmas J, Leflon-Guibout V, et al. Genetic, biochemical characterization and mutagenesis of the chromosomal class A β -lactamase of *Raoultella* (formerly *Klebsiella*) terrigena. *Pathologie Biologie*. 2015;63:158-163.
104. Chen X, Guo S, Liu D, et al. Neonatal septicemia caused by a rare pathogen: *Raoultella planticola*-a report of four cases. *BMC Infectious Diseases*. 2020;20:1-6.
105. Tufa TB, Fuchs A, Feldt T, et al. CTX-M-9 group ESBL-producing *Raoultella planticola* nosocomial infection: first report from sub-Saharan Africa. *Annals of Clinical Microbiology and Antimicrobials*. 2020;19:1-7.
106. Österblad M, Kirveskari J, Hakanen AJ, et al. Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008–11). *Journal of antimicrobial chemotherapy*. 2012;67:2860-2864.
107. Castanheira M, Deshpande LM, DiPersio JR, et al. First descriptions of blaKPC in *Raoultella* spp. (*R. planticola* and *R. ornithinolytica*): report from the SENTRY Antimicrobial Surveillance Program. *Journal of clinical microbiology*. 2009;47:4129-4130.
108. Dohmen W, Bonten MJ, Bos ME, et al. Carriage of extended-spectrum β -lactamases in pig farmers is associated with occurrence in pigs. *Clinical Microbiology and Infection*. 2015;21:917-923.
109. Kola A, Kohler C, Pfeifer Y, et al. High prevalence of extended-spectrum- β -lactamase-producing Enterobacteriaceae in organic and conventional retail chicken meat, Germany. *Journal of Antimicrobial Chemotherapy*. 2012;67:2631-2634.
110. Zheng B, Zhang J, Ji J, Fang Y, Shen P, Ying C, et al. Emergence of *Raoultella ornithinolytica* coproducing IMP-4 and KPC-2 carbapenemases in China. *Antimicrobial agents and chemotherapy*. 2015;59(11):7086-9.
111. Reyes JA, Villavicencio F, Villacís JE, P et al. First report of a clinical isolate of bla OXA-48-carbapenemase producing *Raoultella ornithinolytica* in South America. *Revista Argentina de microbiología*. 2020;52:82-83.
112. Wang S, Xu L, Chi X, et al. Emergence of NDM-1- and CTX-M-3-Producing *Raoultella ornithinolytica* in Human Gut Microbiota. *Frontiers in Microbiology*. 2019;10.
113. Tseng S-P, Wang J-T, Liang C-Y, et al. First report of bla IMP-8 in *Raoultella planticola*. *Antimicrobial agents and chemotherapy*. 2014;58:593-595.
114. Castanheira M, Deshpande LM, DiPersio JR, Kang J, Weinstein MP, Jones RN. First descriptions of bla KPC in *Raoultella* spp. (*R. planticola* and *R. ornithinolytica*): report from the SENTRY Antimicrobial Surveillance Program. *Journal of clinical microbiology*. 2009;47:4129-4130.
115. Pfeifer Y, Schlatterer K, Engelmann E, et al. Emergence of OXA-48-type carbapenemase-producing Enterobacteriaceae in German hospitals. *Antimicrobial agents and chemotherapy*. 2012;56:2125-2128.
116. Dang B, Zhang H, Li Z, et al. Coexistence of the blaNDM-1-carrying plasmid pWLK-NDM and the blaKPC-2-carrying plasmid pWLK-KPC in a *Raoultella ornithinolytica* isolate. *Scientific Reports*. 2020;10:2360.
117. Wang S, Xu L, Chi X, et al. Emergence of NDM-1-and CTX-M-3-producing *Raoultella ornithinolytica* in human gut microbiota. *Frontiers in microbiology*. 2019;10:2678.
118. Li G, Dong Q, Ma L, et al. Management of *Meloidogyne incognita* on tomato with endophytic bacteria and fresh residue of *W. asabia japonica*. *Journal of applied microbiology*. 2014;117:1159-1167.
119. Thies JA, Merrill SB, Corley EL. Red food coloring stain: New, safer procedures for staining nematodes in roots and egg masses on root surfaces. *Journal of Nematology*. 2002;34:179.
120. Nguyen V-N, Ju W-T, Kim Y-J, Jung W-J, et al. Suppression of cucumber root-knot nematode *Meloidogyne incognita* by chitinolytic fungi *Lecanicillium pasalliotae* A-1 and *Lecanicillium antillanum* B-3. *J Chitin Chitosan*. 2014;19:93-99.
121. Abd-Elgawad MM. Optimizing biological control agents for controlling nematodes of tomato in Egypt. *Egyptian Journal of Biological Pest Control*. 2020;30:1-10.
122. Tamang MD, Kim S, Kim S-M, et al. Interaction of *Acinetobacter baumannii* 19606 and 1656-2 with *Acanthamoeba castellanii*. *The Journal of Microbiology*. 2011;49:841-846.
123. Bogitsh BJ, Carter CE, Oeltmann TN. *Human parasitology*: Academic Press; 2018.